Manufacturers and Partners

From removing the regular pain of fingersticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.

Romania, South America, the United States, and the United Kingdom to supply generic drugs to retail chains.

and functions as the pharmaceutical and nutraceutical manufacturing and commercial arm of the holding company. Our focus is on developing unique products and delivery systems for a range of pharmaceutical and nutraceutical segments. We are well-positioned to expand and strengthen the group’s regional footprint to serve the community better. We strongly believe in continuous learning and improving through partnerships and collaborations. Our business partners include leading technology-based pharmaceutical and nutraceutical companies.

Incorporated on April 11, 2008 and based in Metro Manila, Ajanta Pharma Philippines Inc. has quickly established itself as one of the top 35 pharmaceutical corporations distributing prescription only medicines in the Philippines with the introduction of several new pharmaceutical compounds, unique therapeutically optimized fixed dose pharmaceutical combinations and value branded equivalents. Our product portfolio consists of many first to market new pharmaceutical ingredients, innovative fixed dose combinations, and value branded generics. All manufactured in world class CGMP facilities. Ajanta Pharma offers a wild range of product for ANTI-ALLERGY, ANTI-ANGINAL, ANTI-COAGULANT, ANTI-DIABETIC, ANTI-HYPERTENSIVE, ANTI-HYPERURICEMIA, ANTI-LIPIDEMIA, ANTI-NEUROPATHIC PAIN/VITAMIN, ANTI-VERTIGO, BRONCHODILATOR, CARDIOPROTECTIVES UROLOGICALS/ED DRUG.

subsidiary of Novartis until April 9, 2019 when the company completed a shareholder approved 100% spinoff of Alcon eye care devices business from Novartis. Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.

top-eight best-selling products account for nearly all Allergan’s revenue, led by top-seller Botox, an anti-wrinkle treatment. Customers are drug wholesalers, retailers, and distributors, including drugstore chains, hospitals, government agencies, and individual physicians.

gastroenterology. The company is the maker of Botox. Allergan plc was formed in March 2015 when Irish registered Actavis plc acquired U.S.registered Allergan, Inc., and assumed the Allergan name. In 2016, Allergan sold its generic business, Actavis, to Teva for $40.5 billion. In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion. The merged company would be domiciled in the U.S. for tax purposes.

position in respective segments. The efforts in this direction have made ten brands feature in the coveted top 300 brands of the Indian Pharma Market.

creams, ointments, infant nutritional products, and pharmaceutical ingredients. The company was founded by Michael Guy Attridge in 1997 and is headquartered in Durban, South Africaand it is the largest drug company in Africa. Aspen started operating in January 2012 with only a handful of employees. But after a few months, it has rapidly increased to over 100 passionate Filipino workers. With the company’s immediate and continued growth, its commitment becomes stronger. That is to meet the healthcare needs of Filipinos by providing a broad spectrum of high quality, effective, and affordable pharmaceutical products so that ultimately, lives can be sustained one day at a time.

Japanese companies – Yamanouchi Pharmaceutical Co.,Ltd. and Fujisawa Pharmaceutical Co.,Ltd. Astellas inherited strong genes from these two companies and is thus capable of driving its business both powerfully and successfully Astellas intends to continue contributing towards improving the health of Filipino people through the provision of innovative and reliable pharmaceutical products.

breakthroughs developed and implemented by its mother company, B. Braun Melsungen AG, along with subsidiaries in over 61 countries. B. Braun started in the Philippines with just one operating division, retailing sutures and disposables. Now with over 30 years of presence in the country, and with more than 600 sales and service employees, the company presents a diverse approach to patient care, offering exceptional services in dialysis treatments, and cutting-edge healthcare products such as infusion solutions and devices, sutures, surgical instruments, value added drugs, regional anesthesia, hemodialysis machines and disposables, and clinical nutrition. B. Braun draws its innovative strength from the guiding principle “Sharing Expertise,” which cultivates the exchange of information and experience both within the company and with healthcare practitioners and medical institutions. To B. Braun, Sharing Expertise means continuously developing effective solutions through constructive dialog with customers and partners in order to protect health and improve people’s lives.

especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents. The Consumer Health division markets mainly nonprescription (OTC = over-the-counter) products in the dermatology, nutritional supplement, analgesic, digestive health, cold, allergy, sinus and flu categories.

benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.

medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. In 1897, Maxwell Becton and Fairleigh Dickinson founded Becton, Dickinson and Company with a vision to improve outcomes for patients. With more than a century of experience and our global reach, BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories.

beginnings in 1885 when it employed just 28 people in Nieder-Ingelheim, the company has since become a global enterprise. As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

and is now focused in promoting products sourced from reputable European research-based manufacturers and supported by substantial evidence-based scientific literature. We have set a new standard in ethical promotions based on the most appropriate use of our plant-based organic medicinal products and the benefits that may be derived from them as proven by scientific and clinical evidences. These plant-based organic medicinal products are promoted as preferred alternatives to chemically and synthetically manufactured medicines. Our product range focuses mainly in marketing plant-based organic medicinal products proven to be safe and effective in the treatment of ailments in women, infants and children.

of world-class branded products that offer high quality solutions for our caregivers and patients. BSN medical aims to provide an integrated therapy-driven approach – grounded in a broad portfolio of products, enhanced by insights into current therapeutic areas and complemented by a progressive approach to partnerships. BSN medical connects its broad portfolio in Wound Care & related Vascular Diseases, Lymphology and non-invasive Orthopaedics with strong technological competencies to meet the market’s need for reduced complexity and more efficient treatments. With a continuously developing unique and holistic network of integrated therapy solutions, BSN medical consistently supports a continuum of care.

of Kangda locates in Shanghai International Medical Zone. It adheres to the service concept of “We think about what you think”. Currently, Kangda has established the network sales system which includes every branch office in each Province in China. At the same time, Kangda also sets up overseas subsidiaries around the world. The aim of Kangda is to create a complete sales and service platform for the professional medical imaging and dental equipment which covers all the county-level cities by craftsmanship. Now Kangda Medical has a complete product line through importation, R&D and manufacturing partners. The complete product lines includes MRI, CT, Ultrasonics, X-ray Unit, DR, Mammo, C-arm, Mobile X-ray Unit, Bone Densitometer, Animals medical imaging, dental imaging system and dental chair. Kangda Medical will create the intelligent healthcare and establish ecological medical system based on Internet Cloud Technology. The medical imaging remote diagnosis center based on the technology of Kangda Cloud will alleviate the embarrassing situation of uneven distribution of medical resources.

Group and the president and CEO of COMSOL, Inc. FarhadSaeidi is the president of COMSOL AB. At COMSOL, we develop mathematical modeling software that drives new breakthroughs in physics and engineering — and we love what we do. Our flagship product, COMSOL Multiphysics®, is used in all fields of engineering, manufacturing, and scientific research for modeling multiphysics systems. Our customers use the software to understand, predict, innovate, and optimize product designs and processes. We also help our users take simulation one large step further, giving them the tools to create their own simulation apps, based on their models, and then distribute them to collaborators within or outside of the simulation sphere.

most beneficial total solutions with pharmaceuticals and services that contribute to improving quality of life of valued consumers.

The gained expertise in the business gives us opportunity to evaluate and determine the needs of people in any given country and wire our resources accordingly. Our product portfolio ranges from ethical, prescription-driven medicines to OTC products. We work hard to reach new markets and enlarge our portfolio to encompass the needs of nations where we are actively participating in health contribution. DMI ensures quality of its medicines by providing all information and making timely arrangements, as well as performing thoroughgoing quality control at all stages ranging from the manufacturing to the shipment stages of products. We always look for further expanding and developing our business network, and follow the latest pharmaceutical research and development. We are committed to provide our customers with innovative drugs and make valuable contribution to people’s wellbeing.

and development of original products, as well as manufacturing and marketing of strong brands.

that provides clinically-proven medical products, pharmaceuticals and cosmeceuticals to hospitals, clinics and leading drugstores across the nation.

and babies for over 50 years. The company was founded by Dr. Frederik Paulsen Sr and Dr Eva Paulsen in Malmö, Sweden, in 1950, initially as the NordiskaHormonLaboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen’s family originates from that island. Ferring products are used in reproductive health, gastroenterology, urology, orthopaedics and endocrinology.

cleansing procedure that substitutes the function of the kidney in case of kidney failure. Fresenius Medical Care’s corporate headquarters is in Bad Homburg v. d. Höhe, Germany. The headquarters in North America is in Waltham, Massachusetts, the headquarters of Asia-Pacific is located in Hongkong and the headquarters of Latin America is in Rio de Janeiro. Fresenius Medical Care aims to further consolidate its expertise and to use this competence as a basis for sustainable, profitable growth. We aim to continuously improve our patients’ quality of life by offering them high-quality products as well as innovative technologies and treatment concepts.

since 2019. Galderma was formed in 1981 as a joint venture between Nestlé and L’Oréal. Since 2019, it belongs to an investment fund. The company, headed by President & CEO FlemmingOrnskow (ex-Shire), has 33 affiliates in 100 countries with a worldwide network of distributors and employs more than 5,000 people. The parent company is based in Lausanne, Switzerland. Galderma provides a range of products used to treat acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin senescence. Galderma’s products sell in more than 70 countries.

Romania, South America, the United States, and the United Kingdom to supply generic drugs to retail chains.

and market brands trusted by healthcare professionals around the world. We are the only company whose manufacturing facility, in Pakistan, is approved by the World Health Organization, Geneva (WHO). Our Quality Control Laboratory is also the first and only in Pakistan to have been Pre-qualified and approved by WHO. Additionally, our manufacturing facility is the first and only, in Pakistan, certified and approved by a member country of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which comprises more than 50 participating authorities, including US FDA and European Medicines Agency, among others.

after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha’s son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India.

pharmaceutical company committed to improving the health of all individuals worldwide regardless of wealth or geography. We give our first thoughts to patients and their families and are committed to help improve the lives of patients and their families – a principle grounded in Eisai Group’s human health care (hhc) philosophy, which has been embedded into our Article of Incorporation and national programs across the globe. We realize this using the Knowledge Creation SECI (Socialization, Externalization, Combination, Internalization) Model, emphasizing the importance of socialization. Socialization with patients and understanding their tacit knowledge of pleasure, anger, sadness and joy is an essential part of hhc. We recommend all HI-Eisai employees to spend 1% of their business time in socialization, namely spending time together with the patients.

Hovid manufactures primarily generic drugs such as antihistamines, antibiotics, tranquilizers, analgesics, antacids, and diuretics. It also manufactures dietary supplements. Hovid’s products are Halal certified.

presence in 31 countries across the globe. Our manufacturing facilities located in Thailand & Australia, have received international accreditation from reputed health authorities around the world with respect to good manufacturing practices. We export to Asia-Pacific, Middle East, Africa, CIS-Countries, Latin America and Europe. Our business activities across all major stages of the pharmaceutical industry value chain provide us with increased opportunities to pursue growth by realizing potential synergies arising from coordinating our efforts across business segments in our selected markets. Established in 1982, Mega Lifesciences public company limited is actively involved in helping millions of people have access to safe, effective, world class quality nutritional & herbal supplements, OTC and ethical products.

1846, when William Riker founded Riker Laboratories in Manhattan, manufacturing and selling medicines out of a small store. This global site represents a gateway into iNova Pharmaceuticals’ products and services in all our markets. iNova Pharmaceuticals owns and distributes a well known and trusted range of category leading brands. This portfolio includes weight management, cough and cold, throat, pain management, vitamins, health supplements, dermatology, cardiology, respiratory health, allergy and female health products.

Bio-science, and Hemodialysis Products. We believe our success is built upon our client’s satisfaction. Our main line of business ranges from direct importation (through our sister company, Optimum Trading Co.), sales, marketing, distribution and technical services of pharmaceutical, medical disposables, and equipment. Intermed’s greatest asset is its highly motivated and committed technical sales people and distributors covering more than 70% of tertiary and secondary hospitals in the Philippines under the leadership of its President, Maita E. Santos, and Vice-President, Engr. Arnel B. Santos. The products we offer have been manufactured by certified companies who comply and abide by world standards, certified by ISO and FDA from country of origin. We import products from Asia and the USA.

company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. Our manufacturing leadership extends across Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), HydroxychloroquineSulphate (DMARD), Losartan (anti-hypertensive), Metoprolol Succinate (anti-hypertensive), Metoprolol Tartrate (anti-hypertensive), Pyrantel Salts (anthelmintic), and Propranolol (anti-hypertensive) – besides being one of the largest suppliers of these APIs worldwide.

to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients. Ipsen is a French pharmaceutical company headquartered in Paris, France. Ipsen, founded by Henri Beaufour in 1929, In 1983, Ipsen founded the Ipsen Foundation with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt. It has organised 64 colloquia, and it has partnered with the World Health Organization, the FondationNationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.

Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

from what used to be a trading company into a multi-national corporation that controls the whole value chain. The core operation of Kalbe International pretty much of what we have in Kalbe FarmaTbk, starting from New Product Development, Procurement, Production, Marketing (Brand Management), to Logistic and Distribution. Some other function such as Human Resources, Organization Development, Finance, Accounting, and Legal are present to support the whole business processes of Kalbe International. Kalbe International Marketing Division currently presents in 12 countries such as Singapore, Cambodia, Malaysia, Myanmar, Philippines, Vietnam, Sri Lanka, South Africa, Nigeria, Thailand, and UAE. We also exist in 15 other countries through trading partnership. Kalbe’s Formulations are manufactured under stringent quality control of GMP. We provide a comprehensive range of pharmaceutical formulations in every major therapeutic categories of customer needs.

its international turnover in 5 years. Urgo Medical’s expansion outside Western Europe is supported by the group’s international network, which is reinforced by regular acquisitions. In 2014, Urgo Medical was number 3 in the European wound healing market. Our annual turnover was 214 million euros, 63% of which came from export. We have great ambitions for international expansion. These include a new presence in South America, reinforcement of the European network and continued development in Asia. Urgo product has new healing indicators from Urgo Medical to optimise the diagnostic process and make management of wounds easier.

(CNS), including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The company was founded by Hans Lundbeck in 1915, and was initially a trading company supplying a variety of goods to the Danish market, including machinery for manufacturing, aluminium foil, artificial sweeteners, and photographic equipment. Lundbeck entered the pharmaceutical market in 1924, importing medicines and cosmetics from companies based in other European and American countries. By the late 1930s, Lundbeck had begun to produce its own medicinal products and had established its own research department. Production continued during the Second World War, although it was limited due to a lack of raw materials. Lundbeck markets a number of different pharmaceuticals for the treatment of psychiatric and neurological disorders. The most recently launched compounds include: Rexulti (depression and schizophrenia), Brintellix (depression) and AbilifyMaintena (schizophrenia and bipolar 1).

31 countries across the globe. Our manufacturing facilities located in Thailand & Australia, have received international accreditation from reputed health authorities around the world with respect to good manufacturing practices. We export to Asia-Pacific, Middle East, Africa, CIS-Countries, Latin America and Europe. Our business activities across all major stages of the pharmaceutical industry value chain provide us with increased opportunities to pursue growth by realizing potential synergies arising from coordinating our efforts across business segments in our selected markets. Established in 1982, Mega Lifesciences public company limited is actively involved in helping millions of people have access to safe, effective, world class quality nutritional & herbal supplements, OTC and ethical products.

Merck is a global healthcare company with a 125-year history of working to make a difference. Everywhere else, we are known as MSD. Merck has more than 50 prescription products in various therapeutic areas, such as cardiovascular disease, respiratory disease, oncology, neuroscience, infectious diseases, immunology and women’s health.

each phase of development.

Company today has grown four-fold its manpower and is one of the global leaders in cancer pain. With the expansion of the tramadol business in 2007 and the transfer of the consumer-line in 2010, Mundipharma Philippines has established its presence in key areas of the Philippines. Mundipharma Philippines’ office is located in Ortigas Center, Pasig City while the Asia Pacific Regional Office is based in Singapore. Globally, Mundipharma established its operations in Basel, Switzerland in 1957 and has considerably expanded its scope of activities throughout the world through its independent associated companies. Today, Mundipharma has a worldwide licensing and distribution network with sales of licensed products in over 80 countries. These include successful collaborations and licensing in Latin America, the Middle East, Africa and the Asia Pacific, with the establishment of a manufacturing plant in China. Mundipharma Philippines is committed to innovation and is actively seeking to address important areas of pain, consumer health, respiratory, specialty care and oncology. The Company specializes in drug delivery systems and these are applied to our range of products.

a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan went public on the OTC market in February 1973. It is listed on the NASDAQ, and its shares are a component of the NASDAQ Biotechnology, and the S&P 500 indices. The company develops and produces medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women’s healthcare.

pharmaceutical company in 2020. Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our divisions – Innovative Medicines and Sandoz – are supported by functional organizations with global scale.

Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies. In September 2014 the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.

medicines and built up a firm reputation. Nowadays, OEP PH continues to develop in different business including nutricare and dermo-cosmetics to broaden its business scale. OEP PH has been in the market for 14 years and markets affordable and high quality pharmaceutical products for Cardiovascular, Metabolism, Respiratory and Infection. OEP PH not only strives to meet the medical needs of Filipinos, but also supplies the country with affordable medicines to meet business objectives. OEP PH is currently cooperating closely with reputable business partners in product development and production, and searching for more opportunities in its product pipelines. OEP PH’s mission is to enhance the health and quality of life of the population of the Asian region through our entrepreneurial spirit by expertly managing our strategic partners’ and customers’ resources and by providing the public with innovative specialty health care products in the field of medicines, nutricare and dermo-cosmetics.

innovative products and services centering on three core business domains: Cardiovascular Disease, Respiratory Disease, and Pain Management. By so doing, we will help enable healthy lives for people around the world. OMRON’s goal is to reduce cerebrovascular/cardiovascular diseases caused by high blood pressure, such as stroke and heart attack, to near-zero (Zero Events). OMRON can do this by providing highly personalized diagnosis and treatment services based on health data such as blood pressure readings, combined with lifestyle and genetic information, etc. With its advanced drug-free pain relief devices, OMRON aims to help all people lead healthy and active lives by easing chronic pain in the legs, lower back, knees, etc. that can restrict daily activities.

businessmen and a former executive of a multinational company, One Pharma was born. One Pharma is also marketing “over-the-counter” type products. Jamieson of Canada, which is a leading manufacturer of naturally-sourced vitamins, supply these added products to One Pharma.

to a holistic approach to health and well-being of people and are striving to create innovative, thoroughly-original pharmaceutical and nutraceutical products based on our corporate philosophy “Otsuka-people creating new products for better health worldwide”. OPC’s parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan’s No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.

been its raison d’être nor its mission, rightly or wrongly. Paradigm Pharma is engaged in identifying and offering nutraceuticals (natural products with scientific and clinical support ) side-by-side with pharmaceuticals with the aim of offering preventative and treatment options to lessen human dependence on pharmaceuticals. The company licenses-in products from a roster of leading international companies, and secures supplies at lowest possible costs so it can offer medicines and dietary supplements at highly affordable prices to patients, especially in poor countries in Asia, a cornerstone of its founding mission. Paradigm Pharma is a closely-held U.S. company, with autonomously operated units in Asia, and markets products under its own brand names.

component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug. In 2016, Pfizer Inc. was expected to merge with Allergan to create the Ireland-based “Pfizer plc” in a deal that would have been worth $160 billion. The merger was called off in April 2016, however, because of new rules from the United States Treasury against tax inversions, a method of avoiding taxes by merging with a foreign company. The company has made the second-largest pharmaceutical settlement with the United States Department of Justice.

Merchant Wholesalers, Durable Goods sector.

has been dedicated to enabling people with diabetes to live life as normal and active as possible, as well as empowering healthcare professionals to optimally manage their patients’ condition. The current Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. This includes blood glucose meters, lancing devices, insulin delivery systems, and digital solutions for data management, advice, coaching and education. We are looking for opportunities to continuously improve and innovate our portfolio in order to further improve medical outcome and the quality of life of people with diabetes.

global scale and reach in clinical development, manufacturing and commercial operations. Thanks to the Pharmaceuticals Division’s broad-based portfolio, Roche is one of the world’s leading providers of clinically differentiated medicines. Roche Pharma at a glance: Focused on translating excellence in science into breakthrough medicines for patients. One of the leading developers of targeted treatments combined with corresponding diagnostics. The world’s largest biotech company. The world’s leading provider of cancer treatments. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines. By developing products that advance the standard of care for diseases with significant unmet need we are able to meet our obligations not only to shareholders but to society as a whole.

several different trade names – including Dona, Viartril and Arthryl – throughout Europe, South America and Southeast Asia. in many countries, it is the best-selling prescription product for osteoarthritis.

Sanofi-Aventis in 2004, by the merger of Aventis and Sanofi, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi-Aventis is one of Europe’s largest pharmaceutical firms. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world’s largest producer of the latter through its subsidiary Sanofi Pasteur).

bacterial and viral diseases as diphtheria, hepatitis, polio, and meningitis.

oncology, internal medicine, and personal healthcare.

in Asia Pacific, with direct operations established in several countries. Santen also works with distributor partners, in countries such as Indonesia, Myanmar, Cambodia, Pakistan, Sri Lanka and Australia. As a testament to our continued commitment to investing in Asia Pacific, Santen Group entered a strategic five-year collaboration with the Singapore Eye Research Institute (SERI) in 2017. By combining the capabilities of both organizations in ophthalmic R&D, the collaboration aims to develop new technologies in ophthalmology, with a special focus on the diseases prevalent in the region.

immunology. The company’s portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin and rhuman GCSF. All of SciGen’s products have undergone substantial clinical development. SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline. SciGen also in-licenses and distributes pharmaceutical products and medical devices.

the 2018 financial year was €4.2 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 149 countries, achieving 82% of its sales outside France. The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide.The company’s production sites produced 853 million drug boxes in 2013. In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include: Osteoporosis & Osteoarthritis, Orphan Diseases/Cardiology/Diabetes, Cardiology, Diabetes, Metabolic Diseases, Neurology & Oncology.

Healthcare (Siemens Healthineers), and Infrastructure & Cities, which represent the main activities of the company. The company is a prominent maker of medical diagnostics equipment and its medical health-care division, which generates about 12 percent of the company’s total sales, is its second-most profitable unit, after the industrial automation division. The company is a component of the Euro Stoxx 50 stock market index. Siemens and its subsidiaries employ approximately 385,000 people worldwide and reported global revenue of around €87 billion in 2019 according to its earnings release. Siemens offers a wide range of electrical engineering- and electronics-related products and services. Its products can be broadly divided into the following categories: buildings-related products; drives, automation and industrial plant-related products; energy-related products; lighting; medical products; and transportation and logistics-related products.

and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally. STADA focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Consumer Healthcare brands such as Zoflora®, Grippostad®, Snup®, Aqualor®, Vitaprost® and Nizoral® are among the top sellers in their respective product categories. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. Headquartered in Bad Vilbel, Germany, the main drivers of the success are the committed and highly-motivated 11,100 employees (as of December 31, 2019).

and expresses the essence of Takeda’s values and its core commitment to always put patients first. As a global biopharmaceutical leader, it’s important to have a strong corporate philosophy. Since our founding in 1781, we have cultivated our corporate philosophy’s core components, which today we refer to as our Mission, Vision, Values and Strategic Roadmap. These components are explained in detail here. We are committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Our R&D efforts are focused on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Drug firm Torrent Pharmaceuticals on 23 July 2019 reported a 32.51 percent rise in its consolidated net profit to Rs 216 crore for the quarter ended 30 June, mainly on account of robust sales in most geographies.

nutraceutical industry. Trianon International, Inc. is also the official representative in the Philippines of NOW International, Inc., a renowned company based in Bloomingdale Heights, Illinois, U.S.A. which is the top manufacturer of vitamins and food supplements in the United States.

USANA helps further his vision by providing the most advanced supplements science can produce. Families around the globe, as well as thousands of professional and elite athletes, trust their health to USANA every day.

Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Zydus is the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidaemia. The group’s origin can be traced to 1952 when it was founded by Late Mr